Antigen-specific T lymphocyte proliferation decreases over time in advanced chronic hepatitis C

C. Morishima, A. M. Di Bisceglie, A. L. Rothman, H. L. Bonkovsky, K. L. Lindsay, W. M. Lee, M. J. Koziel, R. J. Fontana, H. Y. Kim, E. C. Wright

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

To evaluate T cell immunity in advanced liver disease, antigen-specific lymphoproliferative (LP) responses were prospectively studied in the context of the Hepatitis C Antiviral Long-term Treatment against Cirrhosis trial. Peripheral blood responses to hepatitis C virus (HCV), tetanus and Candida protein antigens were measured at baseline, month 12 (M12), M24, M36 and M48 in 186 patients randomized to either low-dose peginterferon-alfa-2a (PEG-IFN) only or observation. Liver histology was evaluated at baseline, M24 and M48. Patients with cirrhosis (Ishak 5-6) were less likely to have positive LP responses to HCV at baseline than patients with fibrosis (15%vs 29%, P = 0.03) and had lower levels of HCV c100 responses at baseline, M24 and M48 (P = 0.11, P = 0.05, P = 0.02, respectively). For 97 patients with complete longitudinal data, the frequency of positive LP responses to HCV, tetanus and Candida antigens declined over time (P < 0.003), and the slope of this decline was greater in the PEG-IFN treatment group than the observation group (P < 0.02). Lower levels of tetanus LP responses were associated with fibrosis progression and clinical outcomes (P = 0.009). Poorer CD4+ T cell proliferative function was associated with more advanced liver disease in chronic hepatitis C and may be further affected by long-term PEG-IFN treatment.

Original languageEnglish (US)
Pages (from-to)404-413
Number of pages10
JournalJournal of Viral Hepatitis
Volume19
Issue number6
DOIs
StatePublished - Jun 2012

Fingerprint

Chronic Hepatitis C
Hepacivirus
Tetanus
Fibrosis
T-Lymphocytes
Antigens
Candida
Liver Diseases
Observation
Hepatitis C
Antiviral Agents
Immunity
Histology
Therapeutics
Liver
Proteins

Keywords

  • cirrhosis
  • fibrosis
  • hepatitis C virus
  • interferon-alpha
  • lymphoproliferation
  • T cell

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases
  • Virology

Cite this

Morishima, C., Di Bisceglie, A. M., Rothman, A. L., Bonkovsky, H. L., Lindsay, K. L., Lee, W. M., ... Wright, E. C. (2012). Antigen-specific T lymphocyte proliferation decreases over time in advanced chronic hepatitis C. Journal of Viral Hepatitis, 19(6), 404-413. https://doi.org/10.1111/j.1365-2893.2011.01562.x

Antigen-specific T lymphocyte proliferation decreases over time in advanced chronic hepatitis C. / Morishima, C.; Di Bisceglie, A. M.; Rothman, A. L.; Bonkovsky, H. L.; Lindsay, K. L.; Lee, W. M.; Koziel, M. J.; Fontana, R. J.; Kim, H. Y.; Wright, E. C.

In: Journal of Viral Hepatitis, Vol. 19, No. 6, 06.2012, p. 404-413.

Research output: Contribution to journalArticle

Morishima, C, Di Bisceglie, AM, Rothman, AL, Bonkovsky, HL, Lindsay, KL, Lee, WM, Koziel, MJ, Fontana, RJ, Kim, HY & Wright, EC 2012, 'Antigen-specific T lymphocyte proliferation decreases over time in advanced chronic hepatitis C', Journal of Viral Hepatitis, vol. 19, no. 6, pp. 404-413. https://doi.org/10.1111/j.1365-2893.2011.01562.x
Morishima, C. ; Di Bisceglie, A. M. ; Rothman, A. L. ; Bonkovsky, H. L. ; Lindsay, K. L. ; Lee, W. M. ; Koziel, M. J. ; Fontana, R. J. ; Kim, H. Y. ; Wright, E. C. / Antigen-specific T lymphocyte proliferation decreases over time in advanced chronic hepatitis C. In: Journal of Viral Hepatitis. 2012 ; Vol. 19, No. 6. pp. 404-413.
@article{c21c2a95cc4f4475ab340f112b96e451,
title = "Antigen-specific T lymphocyte proliferation decreases over time in advanced chronic hepatitis C",
abstract = "To evaluate T cell immunity in advanced liver disease, antigen-specific lymphoproliferative (LP) responses were prospectively studied in the context of the Hepatitis C Antiviral Long-term Treatment against Cirrhosis trial. Peripheral blood responses to hepatitis C virus (HCV), tetanus and Candida protein antigens were measured at baseline, month 12 (M12), M24, M36 and M48 in 186 patients randomized to either low-dose peginterferon-alfa-2a (PEG-IFN) only or observation. Liver histology was evaluated at baseline, M24 and M48. Patients with cirrhosis (Ishak 5-6) were less likely to have positive LP responses to HCV at baseline than patients with fibrosis (15{\%}vs 29{\%}, P = 0.03) and had lower levels of HCV c100 responses at baseline, M24 and M48 (P = 0.11, P = 0.05, P = 0.02, respectively). For 97 patients with complete longitudinal data, the frequency of positive LP responses to HCV, tetanus and Candida antigens declined over time (P < 0.003), and the slope of this decline was greater in the PEG-IFN treatment group than the observation group (P < 0.02). Lower levels of tetanus LP responses were associated with fibrosis progression and clinical outcomes (P = 0.009). Poorer CD4+ T cell proliferative function was associated with more advanced liver disease in chronic hepatitis C and may be further affected by long-term PEG-IFN treatment.",
keywords = "cirrhosis, fibrosis, hepatitis C virus, interferon-alpha, lymphoproliferation, T cell",
author = "C. Morishima and {Di Bisceglie}, {A. M.} and Rothman, {A. L.} and Bonkovsky, {H. L.} and Lindsay, {K. L.} and Lee, {W. M.} and Koziel, {M. J.} and Fontana, {R. J.} and Kim, {H. Y.} and Wright, {E. C.}",
year = "2012",
month = "6",
doi = "10.1111/j.1365-2893.2011.01562.x",
language = "English (US)",
volume = "19",
pages = "404--413",
journal = "Journal of Viral Hepatitis",
issn = "1352-0504",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Antigen-specific T lymphocyte proliferation decreases over time in advanced chronic hepatitis C

AU - Morishima, C.

AU - Di Bisceglie, A. M.

AU - Rothman, A. L.

AU - Bonkovsky, H. L.

AU - Lindsay, K. L.

AU - Lee, W. M.

AU - Koziel, M. J.

AU - Fontana, R. J.

AU - Kim, H. Y.

AU - Wright, E. C.

PY - 2012/6

Y1 - 2012/6

N2 - To evaluate T cell immunity in advanced liver disease, antigen-specific lymphoproliferative (LP) responses were prospectively studied in the context of the Hepatitis C Antiviral Long-term Treatment against Cirrhosis trial. Peripheral blood responses to hepatitis C virus (HCV), tetanus and Candida protein antigens were measured at baseline, month 12 (M12), M24, M36 and M48 in 186 patients randomized to either low-dose peginterferon-alfa-2a (PEG-IFN) only or observation. Liver histology was evaluated at baseline, M24 and M48. Patients with cirrhosis (Ishak 5-6) were less likely to have positive LP responses to HCV at baseline than patients with fibrosis (15%vs 29%, P = 0.03) and had lower levels of HCV c100 responses at baseline, M24 and M48 (P = 0.11, P = 0.05, P = 0.02, respectively). For 97 patients with complete longitudinal data, the frequency of positive LP responses to HCV, tetanus and Candida antigens declined over time (P < 0.003), and the slope of this decline was greater in the PEG-IFN treatment group than the observation group (P < 0.02). Lower levels of tetanus LP responses were associated with fibrosis progression and clinical outcomes (P = 0.009). Poorer CD4+ T cell proliferative function was associated with more advanced liver disease in chronic hepatitis C and may be further affected by long-term PEG-IFN treatment.

AB - To evaluate T cell immunity in advanced liver disease, antigen-specific lymphoproliferative (LP) responses were prospectively studied in the context of the Hepatitis C Antiviral Long-term Treatment against Cirrhosis trial. Peripheral blood responses to hepatitis C virus (HCV), tetanus and Candida protein antigens were measured at baseline, month 12 (M12), M24, M36 and M48 in 186 patients randomized to either low-dose peginterferon-alfa-2a (PEG-IFN) only or observation. Liver histology was evaluated at baseline, M24 and M48. Patients with cirrhosis (Ishak 5-6) were less likely to have positive LP responses to HCV at baseline than patients with fibrosis (15%vs 29%, P = 0.03) and had lower levels of HCV c100 responses at baseline, M24 and M48 (P = 0.11, P = 0.05, P = 0.02, respectively). For 97 patients with complete longitudinal data, the frequency of positive LP responses to HCV, tetanus and Candida antigens declined over time (P < 0.003), and the slope of this decline was greater in the PEG-IFN treatment group than the observation group (P < 0.02). Lower levels of tetanus LP responses were associated with fibrosis progression and clinical outcomes (P = 0.009). Poorer CD4+ T cell proliferative function was associated with more advanced liver disease in chronic hepatitis C and may be further affected by long-term PEG-IFN treatment.

KW - cirrhosis

KW - fibrosis

KW - hepatitis C virus

KW - interferon-alpha

KW - lymphoproliferation

KW - T cell

UR - http://www.scopus.com/inward/record.url?scp=84861092736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861092736&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2893.2011.01562.x

DO - 10.1111/j.1365-2893.2011.01562.x

M3 - Article

C2 - 22571902

AN - SCOPUS:84861092736

VL - 19

SP - 404

EP - 413

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

SN - 1352-0504

IS - 6

ER -